SYNH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SYNH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Syneos Health's enterprise value is $7,271 Mil. Syneos Health's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was $441 Mil. Therefore, Syneos Health's EV-to-EBITDA for today is 16.50.
The historical rank and industry rank for Syneos Health's EV-to-EBITDA or its related term are showing as below:
During the past 12 years, the highest EV-to-EBITDA of Syneos Health was 70.60. The lowest was 8.99. And the median was 17.67.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-13), Syneos Health's stock price is $42.98. Syneos Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $0.690. Therefore, Syneos Health's PE Ratio for today is 62.29.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
The historical data trend for Syneos Health's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Syneos Health Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
EV-to-EBITDA | Get a 7-Day Free Trial | 14.29 | 18.48 | 18.89 | 21.37 | 10.10 |
Syneos Health Quarterly Data | ||||||||||||||||||||
Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | |
EV-to-EBITDA | Get a 7-Day Free Trial | 15.83 | 11.84 | 10.10 | 11.77 | 15.45 |
For the Diagnostics & Research subindustry, Syneos Health's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, Syneos Health's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Syneos Health's EV-to-EBITDA falls into.
Syneos Health's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | 7270.908 | / | 440.757 | |
= | 16.50 |
Syneos Health's current Enterprise Value is $7,271 Mil.
Syneos Health's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $441 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Syneos Health (NAS:SYNH) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Syneos Health's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 42.98 | / | 0.690 | |
= | 62.29 |
Syneos Health's share price for today is $42.98.
Syneos Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.690.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of Syneos Health's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Michael J. Bonello | officer: Chief Financial Officer | 4130 PARKLAKE AVENUE, SUITE 400, RALEIGH NY 27612 |
Stanford Rudnick | officer: See remarks | C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560-5468 |
Christian Tucat | officer: Chief Business Officer | C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560-5468 |
Michael Lee Brooks | officer: See remarks | C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560 |
Jonathan Olefson | officer: General Counsel & Corp Secty | C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560 |
Michelle Keefe | officer: Pres., Commercial Solutions | C/O SYNEOS HEALTH,INC., 1030 SYNC STREET, MORRISVILLE NC 27560 |
Jason M. Meggs | officer: Chief Financial Officer | C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560 |
Donna Hildebrand Kralowetz | officer: SVP, Chief Accounting Officer | C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560 |
Matthew E. Monaghan | director | ONE INVACARE WAY, ELYRIA OH 44035 |
Alfonso G Zulueta | director | 4925 INDIANA AVE, LISLE IL 60532 |
Barbara W. Bodem | director | C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277 |
Linda S Harty | director | MEDTRONIC PLC, 710 MEDTRONIC PARKWAY NE, LC-150, MINNEAPOLIS MN 55432 |
Alistair Macdonald | officer: Chief Operating Officer | C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560 |
David S. Wilkes | director | ONE BAXTER PARKWAY, DEERFIELD IL 60015 |
Advent International Corp/ma | 10 percent owner | 800 BOYLSTON STREET SUITE 3300, BOSTON MA 02199 |
From GuruFocus
By PRNewswire • 09-21-2023
By Marketwired • 09-20-2023
By Marketwired • 09-26-2023
By PRNewswire • 09-19-2023
By Marketwired • 09-18-2023
By Marketwired • 09-16-2023
By PRNewswire • 09-23-2023
By Marketwired • 09-28-2023
By Marketwired • 09-19-2023
By PRNewswire • 09-19-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.